Molbio Diagnostics was last valued at $1B (post-money). It comes from the $85M Growth investment of Jan 2022. Molbio Diagnostics is a public company.
1 valuation. The latest, $1B post-money, was set by the Growth investment in Jan 2022.
A private valuation is the price agreed in one transaction. The Molbio Diagnostics valuation of $1B is a post-money figure from the Growth investment dated 1 Jan 2022 — the whole company measured after the $85M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $915M .
The valuation holds until the next priced round or secondary sale. A private company founded in 2000 with roughly 2,477 people has no daily price and no order book between rounds.
The closest medical diagnostics / molecular diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. Molbio Diagnostics is listed on BSE/NSE as MOLBIO.
The last valuation is $1B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
